Doses, routes, and pharmacokinetics from the published literature.

Dose numbers from the literature — not recommendations

The doses on this page come from animal studies and three very small human pilots — they are research parameters, not clinical guidelines. BPC-157 has no approved human dosing protocol; any use outside a formal IRB-supervised study operates without a regulatory framework.

In rodent studies, the most common intraperitoneal dose is 10 micrograms per kilogram, though equieffective results have been reported across a six-log range down to 10 picograms per kilogram. In the two published human studies, doses were 10 mg intravesically (interstitial cystitis pilot, n=12) and 10 mg then 20 mg by IV infusion (safety pilot, n=2). The peptide's estimated plasma half-life is under 30 minutes, which means the biological effects observed in animal studies outlast the plasma exposure window by days to weeks — a mismatch not yet explained in human data.

Research context notice

BPC-157 is classified by the FDA as a Category 2 bulk drug substance (effective 2023-09-29), prohibiting its use in compounded medications at both 503A pharmacies and 503B outsourcing facilities. No FDA-approved product containing BPC-157 exists. No active Investigational New Drug (IND) application for BPC-157 is listed in the United States as of 2026. WADA classifies it as a prohibited substance under S0 — Non-Approved Substances (effective 2022).

The doses documented on this page are the doses recorded in the published research literature. They describe what was administered to animals in preclinical studies and to human participants in three small pilot studies under IRB-approved protocols. They are not dosing guidelines, treatment protocols, or clinical recommendations. Translation of rodent doses to human equivalents requires body-surface-area or other conversion methods and is speculative without validated human pharmacokinetic data — which does not currently exist for BPC-157.

Common preclinical doses by route

The rodent research on BPC-157 spans more than three decades and uses a consistent dose architecture across most studies. The following represents the dose parameters as they appear in the published literature.

Intraperitoneal (most common route in preclinical studies):

• 10 μg/kg/day — the most frequently used IP dose, used in Achilles tendon ^[3], quadriceps detachment ^[6][17], wound healing ^[8], cardiac protection ^[10], diclofenac toxicity ^[9], and spinal cord injury studies ^[12]
• 10 ng/kg/day — a lower equieffective dose demonstrated in multiple models alongside the 10 μg/kg dose, including NSAID toxicity ^[9] and cardiac ^[10] models
• 10 pg/kg — explored in select studies demonstrating picomolar efficacy ^[14]
• 20 μg/kg — used in the 2025 ischemia-reperfusion distant organ study ^[11]
• 2 μg/kg — used in the early-treatment phase of the spinal cord injury study ^[12]

Per-oral (drinking water or gavage):

• 0.16 μg/mL in 12 mL/rat/day — the standard per-oral drinking-water concentration used in multiple studies as an equieffective alternative to IP dosing ^{[6][8][9][12][20]}
• 10 ng/kg and 10 μg/kg — per-oral doses (gavage or drinking water) used in quadriceps and spinal cord injury models ^[12][17]

Topical (external wound sites):

• 1 μg/g topical cream — used in wound healing models ^[8] and muscle crush injury ^[7]

Topical ophthalmic:

• 0.4 μg to 0.4 ng per eye (topical eye drops) — used in rat glaucoma models ^[13]

Human pilot studies:

• 10 mg total intravesicular — interstitial cystitis pilot (n=12) ^[18]
• 10 mg IV day 1 / 20 mg IV day 2 (1-hour infusion each) — pharmacokinetic safety pilot (n=2) ^[19]

The therapeutic range studied in the preclinical literature spans approximately 10 pg/kg to 10 μg/kg — a six-log dose range — via multiple routes. Equieffectiveness across this range in multiple models is a distinctive feature of the published literature that has been remarked on by reviewers ^[14][16].

Pharmacokinetics and half-life

BPC-157 has a very short estimated plasma half-life. McGuire et al. (2025) estimated it at less than 30 minutes in the context of a narrative review of the musculoskeletal literature ^[16]. This estimate is consistent with the findings of Lee and Burgess (2025), who reported that plasma BPC-157 levels returned to baseline within 24 hours following IV infusion in two human subjects — a finding compatible with a half-life well under 1 hour ^[19].

Despite this short plasma residence, the biological effects initiated in animal studies appear to persist for days to weeks following cessation of dosing. This mismatch between pharmacokinetic and pharmacodynamic time courses has been observed in other signaling-pathway-activating peptides and is not unique to BPC-157. The mechanistic interpretation is that BPC-157 initiates durable cellular reprogramming (VEGFR2 upregulation, fibroblast migration, macrophage phenotype shift) that outlasts the plasma exposure window.

Stability. BPC-157 was characterized as stable in human gastric juice for greater than 24 hours in the foundational studies that motivated its oral route research ^[14]. This stability in acidic conditions distinguishes it from many other peptides that are rapidly degraded by proteolytic enzymes in the GI tract. Research-grade preparations require refrigeration and protection from light; freeze-dried lyophilized formulations are the typical storage format in research contexts.

Route considerations from the research. The published literature studied BPC-157 across the following routes: intraperitoneal (most common in preclinical), per-oral via drinking water (equieffective in many models), per-oral via gavage, subcutaneous, intragastric, topical cream or gel, topical eye drops, intra-articular injection (human knee pain pilot), intravesicular injection (human interstitial cystitis pilot), and intravenous infusion (human pharmacokinetic pilot). Route-specific pharmacokinetics have not been formally characterized in validated human studies.

What the literature does not establish

The preclinical dose literature for BPC-157 is extensive but does not establish the following, which would be required before any clinical translation could be considered:

• A validated human pharmacokinetic model (no PK study with adequate sample size exists)
• A dose-response relationship in humans (the three published human studies used single fixed doses for single indications with no dose-ranging)
• A safe human dose range established through Phase 1 dose-escalation (NCT02637284 was cancelled with no published results)
• Evidence of efficacy in randomized controlled trials for any human indication
• Long-term safety data in any human population
• Standardized formulation or purity specifications for human-use preparations

McGuire et al. (2025) summarized this gap directly: the compound 'should not be recommended for clinical use in musculoskeletal medicine' pending well-designed human RCTs ^[16]. The FDA's Category 2 classification reflects substantially the same assessment: insufficient human safety data, immunogenicity concerns, and manufacturing impurity risks.